The clinical application of imatinib, a relatively selective inhibitor for BCR-ABL’s tyrosine kinase, has transformed CML, a thitherto intractable disease, into a controllable one [59]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.